// Jia Shi 1,* , Bo Dong 1,* , Jiachao Cao 1,* , Yumin Mao 1 , Wei Guan 1 , Ya Peng 1 and Suinuan Wang 1 1 Department of Neurosurgery, The Third Affiliated Hospital of Soochow University, Changzhou, China * These authors have contributed equally to this work Correspondence to: Suinuan Wang, email: // Ya Peng, email: // Keywords : long non-coding RNAs, glioma, microRNA Received : November 11, 2016 Accepted : January 24, 2017 Published : February 07, 2017 Abstract Glioma is regarded as the most prevalent malignant carcinoma of the central nervous system. Thus, the development of new therapeutic strategies targeting glioma is of significant clinical importance. Long non-coding RNAs (lncRNAs) are functional RNA molecules without a protein-coding function and are reportedly involved in the initiation and progression of glioma. Dysregulation of lncRNAs in glioma is due to activation of several signaling pathways, such as the BRD4-HOTAIR-β-catenin/PDCD4, p53-Hif-H19/IGF2 and CRNDE/mTOR pathways. Furthermore, microRNAs (miRNAs) such as miR-675 also interact with lncRNAs in glioma. Thus, exploring the mechanisms by which lncRNA control processes will be instrumental for devising new effective therapies against glioma.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: